THALES
29.4.2021 10:02:07 CEST | Business Wire | Press release
To guarantee security and complete control of data, Thales and OVHcloud have joined forces to offer Citadel Team encrypted messaging customers a trusted hosting platform that guarantees the sovereignty of their data. Citadel Team customers' data is encrypted and stored at OVHcloud, via its own datacenters located in France.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210429005027/en/
Cybercriminals are taking advantage of the Covid-19 pandemic to infiltrate enterprise networks through vulnerabilities created by the large numbers of people working from home. With the sharp rise in cyberattacks — there have been four times the number of attacks in 2020 than in 2019 according to ANSSI , France’s national agency for information system security. There has also been a growing demand for greater security on data sharing and communication apps; it is more important than ever for companies and users to protect their information, encrypt their data and suitable hosting solution to control how it is stored.
Thales offers professionals a secure instant messaging service, Citadel Team, which requires users to register with a company email address. Already adopted by over a third of CAC 40 companies, the service includes the encryption system used by 50 NATO countries. It provides the guarantee that a company’s data will not be used or sold to third parties. It also ensures that all data is stored in France and that the organization can easily manage user devices themselves. Based on these guarantees, the Citadel development teams have recently obtained the France Cybersecurity 2021 label *.
Citadel Team’s new partner, OVHcloud, shares the same values ofsecurity, sovereignty and data protection. Hosting Citadel Team data in OVHcloud's data centers in France is a guarantee for customers of the application to benefit from an environment of trust. OVHcloud relies on an integrated model that gives it complete control over its value chain: from the design of its servers to the construction and management of its data centers, not forgetting the orchestration of its fiber optic network.
Available free of charge, Citadel Team offers users end-to-end encrypted messaging and voice services on a smartphone or computer, plus a host of premium services, including videoconferencing, group calls and screen sharing. Citadel Team continues to add new functionality tailored to the communication requirements of professionals to offer an all-in-one communication solution without sacrificing data security or usability. Citadel Team is also a member of the Open Trusted Cloud programme, initiated by OVHcloud to federate an ecosystem of trusted players and solutions that respect data protection laws.
“We are especially proud to announce this partnership to our customers and the general public. Thales and OVH have been trusted partners for many years, and by combining our strengths under this new hosting arrangement, we are taking the sovereign Citadel Team solution to the next level to offer our customers the very best data hosting option available.” Pierre-Yves Jolivet, Vice President, Cyber Defence Solutions, Thales.
« We welcome Thales' choice to host Citadel Team data on OVHcloud infrastructures. The combination of our strengths is good news for users looking for guarantees that their data will be respected. They can now be sure to benefit from an alternative, trusted and secure end-to-end solution.» Caroline Comet-Fraigneau, VP France and Benelux, OVHcloud
* The label «France Cybersecurity », is a guarantee for users that the products and services bearing the label are French and that they have clear and well-defined functionalities, with a level of quality attested by an independent jury.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
Thales Group
Defence and Security | Thales Group
View source version on businesswire.com: https://www.businesswire.com/news/home/20210429005027/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom